INTEGRATION PLATFORMS archivos

CAREHAB

Chronic heart failure (CHF) with reduced left ventricular ejection fraction (LVEF) remains a major health problem in developed countries with an increase in prevalence during the last decades related to the ageing of the population. Prevention is the most effective and efficient tool to combat this trend and cardiac rehabilitation programmes (CRP) are the most effective in secondary prevention. These programmes are on an outpatient basis and, despite their proven effectiveness, they are insufficient as less than 20% of CHF patients eligible for RhC attend the programme, a rate that is even lower in the case of Spain, being only 3-4%.

The project pursues the functional development of a telecardiology and telemonitoring tool and subsequent pilot testing in a real controlled environment of an RhC programme for CHF patients through the use of digital health technologies such as IoHT and Big Data to improve the quality of life of patients and the efficiency of health services.

of health spending goes to CCI in developed countries

The project aims to improve the quality of life of patients and the efficiency of health services.

This project has the collaboration of the Hospital Universitario La Paz in Madrid (cardiac rehabilitation unit) and funding from the Ministry of Economic Affairs and Digital Transformation, the European Regional Development Fund of the European Union and Red.es.

To achieve the objectives

2020/0720/00101338 2020-2022

The project is funded by the Ministry of Economic Affairs and Digital Transformation, within the Recovery, Transformation and Resilience Plan and co-funded by the European Union, NextGenerationEU.

Financiers

Related projects

eDSalud

Plataforma de telemedicina multiespecialidad

eDCardio

Telemedicina para la detección y prevención de enfermedades cardiovasculares

eHealth

Creation of eHealth spaces in hotels through the development of a telemedicine platform.

TRADION P

The main objective of this project is the development of an expert system for the diagnosis and personalised treatment of cancer patients that allows the disease to be modelled, selecting, planning, and applying a personalised treatment for each patient. This thereby facilitates the dynamic evaluation of the therapy, the optimisation of results, and improvement in the quality of care, as well as the use of health system resources. The aim is to develop a series of diagnostic tests to enable the integrated and individualised analysis of each case.

In this prototype, a complex multimodal database correlates the patient’s clinical history with histological imaging data, multiple immunofluorescence results, point mutations in genes of interest, alterations in DNA methylation and copy number variations of specific genes via FISH (Fluorescent In Situ Hybridisation).

foundations are collaborating in the project

A complex database correlates the patient’s medical records with health system data and resources.

In order to successfully achieve the project’s aims, a consortium has been formed with INDRA and LORGEN. In addition, Atrys Health collaborates with the San Cecilio University Hospital, the Virgen de las Nieves University Hospital, the Andalusian Tumour Bank Network, the Granada-EASP Cancer Registry, the GENYO research centre in Granada, and the Príncipe Felipe Research Centre in Valencia.

To achieve the objectives

2010-2013

The project is partially co-funded by the Centre for the Development of Industrial Technology (CDTI) and the European Regional Development Fund (ERDF).

Financial blockers

Related projects

ZITOMAB

Second-generation antitumor immunotherapies: antibodies and toxin-conjugated nanobodies using Inteins-ZIP

TRADION P

Expert system for personalized diagnosis and treatment of cancer patients

RAP-ID19

Diagnostic device for rapid detection of COVID-19

SURVEPROST

Molecular signature in liquid biopsy for active surveillance in prostate cancer

ONCOPRECISE

The main aim is to integrate clinical, metabolomic, and transcriptome sequencing data from liquid biopsies of breast cancer patients using next-generation sequencing (NGS) tools into a computer platform for medical decision-making regarding early diagnosis, classification, and pharmacological treatment options.

The project’s technological innovations include the development of new molecular signatures that combine metabolomic and transcriptomic data using NGS techniques that can predict how the disease will evolve compared to therapy and the development of a platform for the integration of clinical data from breast cancer patients. The ONCOPRECISE platform will incorporate deep learning and artificial intelligence systems, based on neural network models, which give it the ability to automatically design new molecular signatures for breast cancer prognosis and monitoring.

264 thousand

euros invested in the project

The platform will apply artificial intelligence to the design of molecular signatures that help to predict breast cancer.

The combination of the study of metabolomics and transcriptomics in liquid biopsies obtained through minimally invasive methods (from blood samples) is a powerful tool for monitoring patients and adapting therapies to the evolutionary state of the tumour, and is a further step forward for precision medicine.

To achieve the objectives

2017-2019

To ensure the success of the project, Atrys Health S.A. is collaborating with the company DATAGEN from Chile, the Hospital Médico Quirúrgico in Jaén, and the Medina Foundation.

This project has been co-funded by the European Regional Development Fund (ERDF) with the aim of promoting technological development, innovation, and quality research.

Financial blockers

Related projects

PRECISESADS

Reclasificación molecular para hallar biomarcadores útiles en enfermedades autoinmunes

ONCOEXPERT

The main objective of this project is the development of an Expert Oncology System to support universal oncology diagnosis and treatment. It is based on previous knowledge derived from the results obtained in the TradionP project, which was developed in a specific region of Andalusia (Granada). The OncoExpert project aims to integrate updated molecular information with greater predictive power, incorporating the latest advances in cancer research. The specific objectives are as follows:

– The integration of the project prior to the development and deployment of OncoExpert to any region or health area, focusing on Andalusia as a community where there are areas of varying tumour rates, and which will allow the complete validation and integration of the Expert System.

– To complement the molecular analysis with the identification of the individual’s whole exome and methylome.

foundations are collaborating in the project

OncoExpert aims to integrate the latest advances in cancer research.

In order to successfully achieve the project’s objective, a consortium has been formed with INDRA, LORGEN, ERA7, and MASTER DIAGNÓSTICA. In addition, Atrys Health collaborates with five foundations from ANDALUSIA: FISEVI (Hosp Virgen del Rocío, Seville): FIBICO (Hospital Reina Sofía, Cordoba); FABIS (Hospital Juan Ramón Jiménez, Huelva); FIMABIS (Hospital Clínico, Málaga) and FIBAO (Hospital Ciudad de Jaén in Jaén).

To achieve the objectives

2013-2014

The project is co-funded by the Centre for the Development of Industrial Technology (CDTI) and the European Regional Development Fund (ERDF).

Financial blockers

Related projects

ONCLIC

Platform for rapid detection of treatable molecular alterations by liquid and solid biopsies.

TheraYAP

Approach for personalized treatment of cancer patients through YAP-TEAD inhibitor.

Modelo predictivo – GBM

Identification of a predictive model of therapeutic option in brain tumors.

ANXARECU

Validation of annexin 2 as a predictor of recurrence in endometrial cancer. Design of new therapeutic strategies

METABREAST

The aim of the project is to develop a non-invasive method to detect breast cancer early and identify of specific molecular subtypes through metabolomics and miRNA analysis in liquid biopsies. These new methods will help to establish the optimal individualised therapy and predict treatment response in breast cancer patients.

The starting hypothesis is based on the existence of alterations in normal metabolic processes that occur in cancer cells and do not occur in healthy cells. This leads to changes in the normal serum concentrations of certain metabolites that can be easily detected and analysed through blood samples.

methods for the personalised diagnosis and treatment of breast cancer

The project develops a non-invasive method for early detection of breast cancer.

Moreover, many studies have associated changes in the profile of miRNAs (small non-coding RNA sequences that regulate gene expression) with different aspects of breast cancer, including early diagnosis, different histological patterns, and disease prognosis.

The set of altered metabolites and the miRNA profile characteristic of the patients would constitute a “signature” indicating the presence of the tumour, which would allow early detection and a more reliable prognosis of the progression of the disease, helping in the selection and monitoring of treatment.

To achieve the objectives

RTC-2016-5674-1 2016-2019

To ensure the success of the project, a consortium has been set up with the Biosanitary Research Foundation in Eastern Andalusia (FIBAO) and the Medina Foundation Centre of Excellence in Innovative Medicines Research in Andalusia.

The project is co-funded by the Ministry of Economy and Competitiveness, within the call Challenges-Collaboration of the State Programme for Research, Development and Innovation Oriented to the Challenges of Society, in the framework of the State Plan for Scientific and Technical Research and Innovation 2013-2016, and by the European Regional Development Fund (ERDF).

Financial blockers

Related projects

PREDICTGYN

Nuevas aproximaciones en el manejo individualizado de pacientes con cáncer ginecológico

RAP-ID19

Dispositivo diagnostico para la detección rápida del COVID-19

iDoctus-Hacking ético

The aim of the project was to develop a platform to aid the early detection and neutralisation of infectious diseases by identifying the local incidence of pathogens and their resistance in real time. This identification is based on the information contained in clinical analyses carried out on patients, once captured, anonymised, and geolocated using big data and ethical hacking techniques.

This approach will provide the doctor with real-time information contained in the microbiological analyses of all the laboratories located in the patient’s vicinity.

cutting-edge technologies applied to research

The platform uses big data and ethical hacking techniques to identify pathogens.

In order to successfully achieve the project’s objectives, Atrys Health has formed a consortium with the companies eDoctors Soluciones and BlueLiv.

To achieve the objectives

TSI-100105-2014-73 2013-2015

The project is funded by the Digital Economy and Society Strategic Action Programme (AEESD in Spanish).

Financial backers

Related projects

TRADION P

Expert system for personalized diagnosis and treatment of cancer patients

ONCOEXPERT

Biotechnology for oncology diagnosis and treatment. Expert Oncology System

ONCOPRECISE

Platform for decision making in oncology diagnosis and treatment.